Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [RIP-seq]

ABSTRACT: ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [RIP-seq]

PROVIDER: PRJNA934547 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23379900_1.fastq.gz	Fastqsanger.gz
	SRR23379900_2.fastq.gz	Fastqsanger.gz
	SRR23379901_1.fastq.gz	Fastqsanger.gz
	SRR23379901_2.fastq.gz	Fastqsanger.gz
	SRR23379902_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [RIP-seq]

2023-10-23 | GSE224910 | GEO

ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [RIPseq-ELAVL3&R1D]

2023-10-23 | GSE236365 | GEO

ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [RIPseq-ELAVL3&R1D]

Project description:ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [RIPseq-ELAVL3&R1D]

| PRJNA990712 | ENA

ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [NCI-H660]

Project description:Here we demonstrated that the RNA-binding protein ELAVL3 is specifically upregulated in NEPC, and that overexpression of ELAVL3 alone sufficiently induce neuroendocrine phenotype in prostate adenocarcinoma. Pharmacological inhibition of ELAVL3 with pyrvinium pamoate, an FDA-approved drug, effectively suppressed tumor growth, reduced the risk of metastases, and improved the survival of NEPC mice models.

2023-10-23 | GSE222469 | GEO

ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [LNCaP/AR/shTP53/shRB1]

2023-10-23 | GSE224909 | GEO

ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [NCI-H660]

Project description:ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [NCI-H660]

| PRJNA922169 | ENA

ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [LNCaP/AR/shTP53/shRB1]

Project description:ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [LNCaP/AR/shTP53/shRB1]

| PRJNA934548 | ENA

The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer

Project description:The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer

| PRJNA933106 | ENA

Expression profiling of murine MYCN-driven neuroendocrine tumor from LSL-MYCN;hGFAP-Cre mice.

Project description:MYCN overexpression is a hallmark of many tumors originating from neural cell precursors. We generated a transgenic mouse with Cre-conditional induction of MYCN in glial fibre acidic protein (GFAP) expressing cells resulting in the development of neuroendocrine tumors of the pancreas and the brain. The expression profiles of nine tumors from pancreas and three brain tumors were compared to non-malignant pancreas controls (GSM771025.CEL-GSM771027.CEL) from wildtype mice Expression profiles of tumors and controls were analysed using GSEA and ANOVA.

2016-03-01 | E-GEOD-73466 | biostudies-arrayexpress

Expression profiling of murine MYCN-driven neuroendocrine tumor from LSL-MYCN;hGFAP-Cre mice.

2016-03-01 | GSE73466 | GEO